IN2014MN01998A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01998A
IN2014MN01998A IN1998MUN2014A IN2014MN01998A IN 2014MN01998 A IN2014MN01998 A IN 2014MN01998A IN 1998MUN2014 A IN1998MUN2014 A IN 1998MUN2014A IN 2014MN01998 A IN2014MN01998 A IN 2014MN01998A
Authority
IN
India
Prior art keywords
particulate
metal salts
ynamide
dihydroquinazolin
pyrazolo
Prior art date
Application number
Inventor
Rudy Laurent Maria Broeckx
Walter Ferdinand Maria Filliers
Patrick Hubert J Nieste
Alex Herman Copmans
Filip Marcel C Vanhoutte
Carina Leys
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of IN2014MN01998A publication Critical patent/IN2014MN01998A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

There is provided inter alia a dry powder pharmaceutical formulation for inhalation comprising: (i) 6 (2 ((4 amino 3 (3 hydroxyphenyl) 1 H pyrazolo[3 4 d]pyrimidin 1 yl) methyl) 3 (2 chlorobenzyl) 4 oxo 3 4 dihydroquinazolin 5 yl) N N bis(2 methoxyethyl)hex 5 ynamide or a pharmaceutically acceptable salt thereof including all stereoisomers tautomers and isotopic derivatives thereof and solvates thereof in particulate form as active ingredient; (ii) particulate lactose as carrier; and (iii) a particulate stabilizing agent selected from metal salts of stearic acid such as magnesium stearate and metal salts of stearyl fumarate.
IN1998MUN2014 2012-03-13 2013-03-13 IN2014MN01998A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13
PCT/GB2013/050623 WO2013136075A1 (en) 2012-03-13 2013-03-13 Novel pharmaceutical formulations

Publications (1)

Publication Number Publication Date
IN2014MN01998A true IN2014MN01998A (en) 2015-08-14

Family

ID=49160309

Family Applications (2)

Application Number Title Priority Date Filing Date
IN1998MUN2014 IN2014MN01998A (en) 2012-03-13 2013-03-13
IN2000MUN2014 IN2014MN02000A (en) 2012-03-13 2013-03-13

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN2000MUN2014 IN2014MN02000A (en) 2012-03-13 2013-03-13

Country Status (36)

Country Link
US (3) US20150099768A1 (en)
EP (2) EP2825202B1 (en)
JP (3) JP6189874B2 (en)
KR (2) KR20140131971A (en)
CN (2) CN104284679B (en)
AU (2) AU2013234081B2 (en)
CA (2) CA2864652A1 (en)
CL (2) CL2014002385A1 (en)
CO (2) CO7061079A2 (en)
CR (2) CR20140416A (en)
CY (1) CY1118565T1 (en)
DK (1) DK2834244T3 (en)
EA (2) EA023715B1 (en)
EC (2) ECSP14018142A (en)
ES (2) ES2600705T3 (en)
GT (2) GT201400182A (en)
HK (2) HK1203487A1 (en)
HR (1) HRP20161383T1 (en)
HU (1) HUE029420T2 (en)
IL (2) IL233886A (en)
IN (2) IN2014MN01998A (en)
LT (1) LT2834244T (en)
MX (2) MX355299B (en)
MY (1) MY171125A (en)
NI (2) NI201400100A (en)
NZ (2) NZ628072A (en)
PE (2) PE20142342A1 (en)
PH (2) PH12014501713A1 (en)
PL (1) PL2834244T3 (en)
PT (1) PT2834244T (en)
SG (2) SG11201404519UA (en)
SI (1) SI2834244T1 (en)
TW (2) TWI586378B (en)
UA (1) UA115544C2 (en)
WO (2) WO2013136076A1 (en)
ZA (2) ZA201407373B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
KR20140131971A (en) 2012-03-13 2014-11-14 레스피버트 리미티드 Novel pharmaceutical formulations
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
AR095353A1 (en) 2013-03-15 2015-10-07 Respivert Ltd COMPOUND
JO3279B1 (en) 2013-03-15 2018-09-16 Respivert Ltd 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
BR112016007467B1 (en) 2013-10-04 2022-09-20 Infinity Pharmaceuticals, Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
CU24428B1 (en) 2014-07-04 2019-06-04 Lupin Ltd QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS
WO2016005443A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017177966A1 (en) 2016-04-15 2017-10-19 正大天晴药业集团股份有限公司 Inhaled preparation of isoglycyrrhizic acid or salt thereof and use in preparing drugs for treating respiratory system diseases
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
DE60004781T2 (en) 1999-01-11 2004-07-08 Princeton University KINASE INHIBITORS WITH HIGH AFFINITY FOR TARGET DETECTION AND THEIR USE
BR9917246A (en) 1999-03-05 2002-03-26 Chiesi Farma Spa Advanced pharmaceutical compositions for inhalation powder
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1186324C (en) 2000-04-27 2005-01-26 山之内制药株式会社 Condensed heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20040132732A1 (en) 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
WO2004080966A1 (en) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
WO2005004845A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
WO2005012221A1 (en) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. Diphenyl ether compound, process for producing the same, and use
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
LT2612862T (en) 2004-05-13 2017-01-25 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
MX2007002886A (en) 2004-09-13 2007-05-16 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient.
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
NZ571182A (en) 2006-04-04 2010-09-30 Univ California Pyrazolo[3,4-d]pyrimidines
CN101506211B (en) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 Kinase antagonists
EP2032605A2 (en) 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
CN101506198A (en) 2006-06-29 2009-08-12 先灵公司 Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
JP2010526120A (en) 2007-05-09 2010-07-29 ノバルティス アーゲー Substituted imidazopyridazines as PI3K lipid kinase inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
MY191407A (en) 2008-01-04 2022-06-27 Intellikine Llc Certain chemical entities, compositions and methods
JP5731978B2 (en) 2008-09-26 2015-06-10 インテリカイン， エルエルシー Heterocyclic kinase inhibitor
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
CA2745280A1 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
NZ595307A (en) 2009-03-24 2013-11-29 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2011015037A1 (en) 2009-08-05 2011-02-10 The University Of Hongkong Antiviral compounds and methods of making and using there of cross reference to related applications
GB0918249D0 (en) * 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (en) * 2010-03-29 2010-12-22 山东京卫制药有限公司 Drug administration device with voice prompt function
CN201692450U (en) * 2010-06-22 2011-01-05 于清 High-efficiency dry powder sucker for drug delivery
JP5792308B2 (en) * 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Dry powder inhalation drug product exhibiting moisture control characteristics and method of administration thereof
TR201901644T4 (en) 2010-09-30 2019-02-21 Chiesi Farm Spa Magnesium stearate in dry powder formulations for inhalation. use of.
UY33337A (en) 2010-10-18 2011-10-31 Respivert Ltd SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
CN202154919U (en) * 2011-05-03 2012-03-07 王晓明 Anti-cross-infection aerosol inhalation device
KR20140131971A (en) 2012-03-13 2014-11-14 레스피버트 리미티드 Novel pharmaceutical formulations

Also Published As

Publication number Publication date
NI201400101A (en) 2016-11-30
MY171125A (en) 2019-09-26
ZA201407373B (en) 2016-10-26
TWI617561B (en) 2018-03-11
MX357170B (en) 2018-06-27
EA201491675A1 (en) 2014-12-30
CL2014002386A1 (en) 2015-02-27
CY1118565T1 (en) 2017-07-12
ZA201407374B (en) 2016-10-26
MX2014010990A (en) 2014-10-13
PH12014501713A1 (en) 2014-10-13
GT201400182A (en) 2015-09-17
HK1203812A1 (en) 2015-11-06
CN104302650B (en) 2017-07-18
EP2834244B1 (en) 2016-08-10
CR20140416A (en) 2014-10-31
AU2013234081A1 (en) 2014-08-21
ECSP14018142A (en) 2015-06-30
EP2834244A1 (en) 2015-02-11
ES2600705T3 (en) 2017-02-10
EA201491674A1 (en) 2014-12-30
CO7061079A2 (en) 2014-09-19
PL2834244T3 (en) 2017-01-31
US20150099768A1 (en) 2015-04-09
HK1203487A1 (en) 2015-10-30
US20170239256A1 (en) 2017-08-24
IN2014MN02000A (en) 2015-08-14
CN104284679B (en) 2017-08-04
TWI586378B (en) 2017-06-11
US20150105408A1 (en) 2015-04-16
NZ627963A (en) 2015-08-28
IL233883A0 (en) 2014-09-30
MX2014010991A (en) 2014-10-13
EA023715B1 (en) 2016-07-29
ES2650791T3 (en) 2018-01-22
PT2834244T (en) 2016-11-03
AU2013234081B2 (en) 2017-02-02
MX355299B (en) 2018-04-11
CA2864643A1 (en) 2013-09-19
KR20140131971A (en) 2014-11-14
HUE029420T2 (en) 2017-02-28
PE20142342A1 (en) 2015-01-16
TW201350139A (en) 2013-12-16
TW201400484A (en) 2014-01-01
CL2014002385A1 (en) 2015-01-09
GT201400183A (en) 2015-07-08
NZ628072A (en) 2015-08-28
KR20140141596A (en) 2014-12-10
JP2018008992A (en) 2018-01-18
CA2864652A1 (en) 2013-09-19
JP6189874B2 (en) 2017-08-30
AU2013234080B2 (en) 2016-12-22
CR20140417A (en) 2014-10-31
NI201400100A (en) 2015-01-12
EA025465B1 (en) 2016-12-30
CN104302650A (en) 2015-01-21
LT2834244T (en) 2016-11-10
PH12014501922A1 (en) 2014-11-24
WO2013136075A1 (en) 2013-09-19
DK2834244T3 (en) 2016-11-28
UA115544C2 (en) 2017-11-27
EP2825202B1 (en) 2017-09-06
AU2013234080A1 (en) 2014-08-21
HRP20161383T1 (en) 2016-12-02
CO7051030A2 (en) 2014-09-10
SI2834244T1 (en) 2016-12-30
IL233886A (en) 2017-12-31
SG11201404519UA (en) 2014-10-30
ECSP14018630A (en) 2015-09-30
JP2015509973A (en) 2015-04-02
EP2825202A1 (en) 2015-01-21
JP2015509972A (en) 2015-04-02
US9642799B2 (en) 2017-05-09
SG11201404522VA (en) 2014-10-30
WO2013136076A1 (en) 2013-09-19
PE20141964A1 (en) 2014-12-01
CN104284679A (en) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2014MN01998A (en)
NZ629442A (en) Heterocyclyl compounds as mek inhibitors
JP2013538214A5 (en)
TN2012000544A1 (en) Soluble guanylate cyclase activators
MX2020014163A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(py ridin-2-yl)benzamide.
NZ597963A (en) A pharmaceutical formulation comprising n-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-n’-(1,1-dimethylethyl)-urea in the form of a base or a salt thereof
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
MX2015010971A (en) Novel pyrazole derivative.
MY158193A (en) Morpholino pyrimidines and their use in therapy
PH12017500479A1 (en) Liquid inhalation formulation comprising prl554
RS53898B1 (en) Quinazolin-4(3h)-one derivatives used as pi3 kinase inhibitors
JP2015509972A5 (en)
RU2017134002A (en) STABLE TETRAHYDROBIOPTERIN COMPOSITIONS
MX2022000826A (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase.
MX336505B (en) Methods and compositions for reducing body fat and adipocytes.
MX2016012669A (en) SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZ OLE DERIVATIVES AS ROS1 INHIBITORS.
IN2014DN01619A (en)
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
UA93355C2 (en) Formulation of suberoylanilide hydroxamic acid and method for producing same
TW200727892A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
MX339685B (en) New (trimethoxyphenylamino)pyrimidinyl formulations.
HRP20200472T1 (en) Treatment of alopecia areata
IN2014CN02850A (en)
NZ701274A (en) Oral b12 therapy
CA3010857A1 (en) Pharmaceutical composition comprising nebivolol with improved dissolution rate